tau small interfering ribonucleic acid

Tau small interfering ribonucleic acid is a **tau-lowering RNA interference therapeutic concept** comprising small interfering RNA molecules designed to silence **MAPT mRNA**, thereby reducing production of tau protein in the central nervous system. This approach is being pursued for **Alzheimer's disease and other tauopathies**, based on the rationale that lowering intracellular tau may reduce tau aggregation, neurofibrillary tangle formation, and downstream neurodegeneration. The term as given is **not specific to one single named drug candidate** and can refer to multiple investigational programs, including intrathecal and subcutaneous CNS-directed MAPT siRNA candidates being developed by companies such as Eli Lilly, Arrowhead Pharmaceuticals, and Alnylam in preclinical or early clinical development.

Other names

tau small interfering ribonucleic acidtau siRNAMAPT siRNAmicrotubule-associated protein tau small interfering ribonucleic acid